Edible Algae and Blood Pressure: Why Species Matters

Edible algae may lower blood pressure, but the category is far too broad to guide a purchase. The best human evidence favors chlorella, while spirulina has a narrower diastolic-pressure signal. Nori and kelp have a credible nitrate-to-nitric-oxide mechanism, yet targeted blood-pressure trials of those foods are missing.

That distinction matters if you have hypertension. A 2025 systematic review and meta-analysis of randomized controlled trials concluded that algae-related blood-pressure effects differ by species, dose, and the health of the participants. The evidence supports a cautious hierarchy, not a blanket claim that every green powder or seaweed snack acts like an antihypertensive drug.

Chlorella has the most complete signal: more than 4 g per day for at least eight weeks reduced both systolic and diastolic blood pressure in hypertensive participants in the prior meta-analysis identified by the 2025 review.

Chlorella has the best case for blood pressure

In Casas-Agustench et al.'s 2025 systematic review and meta-analysis, chlorella stood apart from the other algae. The review reports that a previous meta-analysis found significant reductions in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) among hypertensive participants when chlorella intake exceeded 4 g daily for at least eight weeks.

This is the only dual-endpoint signal identified in the algae literature summarized by that review. SBP matters especially because it is the stronger predictor of cardiovascular events in clinical practice. Still, the publication does not provide recoverable effect sizes or confidence intervals for this result, so readers cannot judge the reduction in millimeters of mercury or whether it reached a clinically meaningful threshold such as 5 mmHg of SBP.

The dose and duration are useful, but they do not turn chlorella into a substitute for prescribed treatment, sodium reduction, exercise, or a DASH-style dietary pattern. No direct trials in this evidence compared chlorella with those interventions or with antihypertensive medication.

Spirulina: a diastolic signal, not a full verdict

Spirulina looks somewhat promising, but the result is more limited. Three of the four prior meta-analyses summarized by Casas-Agustench et al. found significant reductions in DBP only, including analyses of spirulina and pooled algae interventions. Those analyses combined healthy people with participants who had type 2 diabetes, hypertension, ischemic heart disease, dyslipidemia, or HIV. Such mixed populations make it difficult to know how much benefit a person with established hypertension should expect.

A separate 2025 systematic review of spirulina supplementation also reported an antihypertensive signal alongside changes in metabolic outcomes. Its available summary does not provide a usable blood-pressure effect size, confidence interval, dose, or duration. That supports consistency of direction, not precision.

Spirulina contains compounds that could affect blood pressure. A 2025 mechanistic review describes ACE-inhibitory peptides in spirulina and chlorella. Blocking angiotensin-converting enzyme can reduce angiotensin II-driven vasoconstriction. Spirulina also contains phycocyanin, a pigment with antioxidant activity that may help address oxidative stress relevant to endothelial function. These mechanisms are biologically plausible; they do not prove that a given spirulina product lowers a given person's blood pressure.

Nori and kelp rely on a plausible pathway, not direct trials

Nori, from Porphyra species, and kelp, from Laminaria species, belong to different algal groups but share a relevant feature: inorganic nitrate. Dietary nitrate can raise nitrate availability and contribute to nitric oxide production, which promotes vasodilation.

A 2025 GRADE-assessed dose-response meta-analysis of randomized trials found that dietary nitrate supplementation, with higher plasma nitrate, significantly reduced both SBP and DBP and improved vascular-health biomarkers, including endothelial function. That evidence supports the pathway. The trials evaluated inorganic nitrate supplements, not isolated nori or kelp interventions.

So eating nori or kelp as food is reasonable if you enjoy it and it fits your diet, but it would overstate the evidence to call either a proven blood-pressure treatment. The algae review identified no randomized trials that tested nori or kelp specifically as antihypertensive interventions.

Brown seaweeds also contain fucoidan, a polysaccharide discussed in a 2023 review of algae food products for its potential effects on vascular inflammation. This remains mechanistic context, not evidence of a measured blood-pressure effect from a specific seaweed product.

Why the literature still cannot settle the question

The positive findings deserve restraint because the underlying literature is small. All prior algae blood-pressure meta-analyses summarized in the 2025 review included fewer than 500 participants combined. Small pooled samples produce imprecise estimates and raise the risk that an apparently positive result will fail to replicate.

The studies also differ in species, doses, formats, intervention length, and participant health. Pooling a normotensive participant with someone who has uncontrolled hypertension can blur a treatment effect. A reduction in DBP across heterogeneous cohorts is physiologically meaningful, but it does not establish the broader SBP-and-DBP profile clinicians usually seek in hypertension care.

No null or negative algae blood-pressure trials appeared in the retrieved literature. That pattern may reflect publication bias, in which positive studies are more likely to be published, although the available information does not allow a formal estimate of that bias. A 2026 narrative review of clinical algae research reaches a similar practical conclusion: cardiometabolic findings are favorable in direction but limited by study size and duration.

Safety is not a blank check

The reviewed algae literature contained no safety, toxicology, or contamination data. That absence does not establish safety, especially for multi-gram daily supplementation. Concerns such as product contamination and possible interactions with drugs were not addressed by these studies. Choose products from suppliers that provide credible testing information, and discuss a supplement with a clinician or pharmacist if you take blood-pressure medication or have a medical condition.

A practical ranking

• Chlorella: The strongest evidence in this literature for people with hypertension. The reported threshold was more than 4 g daily for at least eight weeks, with significant reductions in SBP and DBP.
• Spirulina: A reasonable secondary option if you already use it, with repeated DBP-only findings across mixed populations. Do not assume it will lower SBP.
• Nori and kelp: Their nitrate content gives them a credible nitric-oxide pathway, but direct species-specific blood-pressure trials are absent.

The sensible conclusion is narrow. Chlorella has the best randomized-trial signal for blood pressure, spirulina has a less complete one, and nitrate-rich seaweeds remain an evidence-informed food choice rather than a tested treatment. Measure your blood pressure, keep proven care in place, and do not let a flattering label do the peer review.